Jaktinib (Tofacitinib) is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Jaktinib (Tofacitinib) film-coated tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs)
Advancing global health through high-quality APIs, intermediates, and surgical products. Trusted solutions driven by innovation, quality, and care.
Copyright © 2025 Healnith Pharmaceuticals All rights reserved.